Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2022 - 2025)

Historic Long-Term Deferred Tax for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Q3 2025 value amounting to $201.3 million.

  • Kiniksa Pharmaceuticals International's Long-Term Deferred Tax fell 322.18% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.3 million, marking a year-over-year decrease of 322.18%. This contributed to the annual value of $211.2 million for FY2024, which is 370.84% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax stood at $201.3 million, which was down 322.18% from $205.5 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Long-Term Deferred Tax high stood at $219.3 million for Q4 2023, and its period low was $184.4 million during Q1 2023.
  • Moreover, its 4-year median value for Long-Term Deferred Tax was $204.3 million (2024), whereas its average is $202.0 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax surged by 1821.5% in 2023 and then plummeted by 370.84% in 2024.
  • Kiniksa Pharmaceuticals International's Long-Term Deferred Tax (Quarter) stood at $185.5 million in 2022, then rose by 18.22% to $219.3 million in 2023, then dropped by 3.71% to $211.2 million in 2024, then dropped by 4.67% to $201.3 million in 2025.
  • Its Long-Term Deferred Tax was $201.3 million in Q3 2025, compared to $205.5 million in Q2 2025 and $208.2 million in Q1 2025.